Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.

Josephine Louella Feliciano,Dylan McLoone,Yingxin Xu,Ruben G W Quek,Andreas Kuznik,Jean-Francois Pouliot,Giuseppe Gullo,Petra Rietschel,Patricia Guyot,Gerasimos Konidaris,Keith Chan,Sam Keeping,Florence R Wilson,Nick Freemantle

Frontiers in Oncology（2022）

Cited 3|Views11

No score

Abstract

After adjusting for treatment crossover and continued cemiplimab treatment after progression with the addition of histology-specific chemotherapy observed in EMPOWER-Lung 1, cemiplimab continued to demonstrate a clinically important and statistically significant OS benefit versus chemotherapy, consistent with the primary analysis.

Translated text

Key words

EMPOWER-lung 1,cemiplimab,chemotherapy,crossover design,first-line treatment,non-small cell lung cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined